With drug spending slowing in the traditional biopharmaceutical markets, the emerging markets represent the strongest untapped growth opportunity – but market entry is fraught with challenges, uncertainties, and escalating costs.
Our latest study Payer - Industry Partnerships in the Emerging Markets: Best Practices for Successful Market Access of New Pharmaceuticals explores the types of payer-industry strategic partnerships that are emerging, as well as the best practices for establishing such partnerships, and the critical success factors pharma companies need to consider in the developing world.
Using primary research of stakeholders, this study will include a chapter on Supra-National Organizations, as well as country-specific chapters covering China, Brazil, India, Mexico, Turkey, and Russia.
Download sample files from the study:
- Sample Analysis for Payer- Industry Partnerships in Emerging Markets (PDF, 2 MB)
- Chapter extract with table of contents focussed on China (PDF, 587 KB)
Key questions answered include:
- Who are the payers in each market at the national, regional, and local level?
- What types of partnerships currently exist in each market?
- What are the strengths and weaknesses of these current models?
- How viable are these current models in light of market trends?
- How are the opportunities for partnerships evolving in each market?
- What new and innovative partnership models are emerging in each market?